Calcium channel blocker use is associated with lower fasting serum glucose among adults with diabetes from the REGARDS study

Highlights • Diabetes does not have a definitive treatment, but in recent studies of mouse models of type 1 diabetes, verapamil, a commonly used medication for a variety of conditions, decreased β-cell apoptosis and restored insulin levels, essentially rescuing mice from the disease. • The role of v...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes research and clinical practice 2016-05, Vol.115, p.115-121
Main Authors: Khodneva, Yulia, Shalev, Anath, Frank, Stuart J, Carson, April P, Safford, Monika M
Format: Article
Language:English
Subjects:
Adult
Aged
Biomarkers - blood
Blood Glucose - drug effects
Blood Glucose - metabolism
Ca2+ channel blockers
Calcium Channel Blockers - administration & dosage
Diabetes
Diabetes Mellitus - drug therapy
Diabetes Mellitus - epidemiology
Dose-Response Relationship, Drug
Endocrinology & Metabolism
Fasting - blood
Female
Humans
Insulin - blood
Male
Middle Aged
Prognosis
Risk Factors
Stroke - blood
Stroke - epidemiology
Stroke - etiology
Survival Rate - trends
United States - epidemiology
Verapamil
Verapamil - administration & dosage
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Diabetes does not have a definitive treatment, but in recent studies of mouse models of type 1 diabetes, verapamil, a commonly used medication for a variety of conditions, decreased β-cell apoptosis and restored insulin levels, essentially rescuing mice from the disease. • The role of verapamil as a possible anti-diabetic agent in humans is highly novel and unexplored. • Verapamil use was associated with significantly lower fasting blood glucose levels among participants with diabetes from a population-based cohort, controlling for a host of covariates.
ISSN:0168-8227
1872-8227
DOI:10.1016/j.diabres.2016.01.021